Deep learning approach to predict sentinel lymph node status directly from routine histology of primary melanoma tumours.

Journal: European journal of cancer (Oxford, England : 1990)
Published Date: Jul 20, 2021

Abstract

AIM: Sentinel lymph node status is a central prognostic factor for melanomas. However, the surgical excision involves some risks for affected patients. In this study, we therefore aimed to develop a digital biomarker that can predict lymph node metastasis non-invasively from digitised H&E slides of primary melanoma tumours.

Authors

  • Titus J Brinker
    National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Lennard Kiehl
    Digital Biomarkers for Oncology Group, National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany.
  • Max Schmitt
    National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany.
  • Tanja B Jutzi
    Digital Biomarkers for Oncology Group, National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany.
  • Eva I Krieghoff-Henning
    Digital Biomarkers for Oncology Group, National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany.
  • Dieter Krahl
    Private Laboratory of Dermatohistopathology, Mönchhofstraße 52, 69120 Heidelberg.
  • Heinz Kutzner
    Dermatopathology Laboratory, Friedrichshafen, Germany.
  • Patrick Gholam
    Department of Dermatology, University Hospital Heidelberg, Heidelberg. Germany.
  • Sebastian Haferkamp
    Department of Dermatology, University Hospital Regensburg, Regensburg, Germany.
  • Joachim Klode
    Department of Dermatology, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany.
  • Dirk Schadendorf
    Department of Dermatology, University Hospital Essen, 45147 Essen, Germany.
  • Achim Hekler
    National Center for Tumor Diseases, Department of Translational Oncology, German Cancer Research Center, Heidelberg, Germany.
  • Stefan Fröhling
    National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Im Neuenheimer Feld 460, 69120 Heidelberg, Germany.
  • Jakob N Kather
    Department of Gastroenterology, University Hospital RWTH Aachen, Aachen, Germany. jakob.kather@gmail.com.
  • Sarah Haggenmüller
    Digital Biomarkers for Oncology Group, National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Christof von Kalle
    National Center for Tumor Diseases, Department of Translational Oncology, German Cancer Research Center, Heidelberg, Germany.
  • Markus Heppt
    Department of Dermatology, University Hospital Erlangen, Erlangen, Germany.
  • Franz Hilke
    Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin, Berlin, Germany.
  • Kamran Ghoreschi
    Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Markus Tiemann
    Institute for Hematopathology Hamburg, Hamburg, Germany.
  • Ulrike Wehkamp
    Department of Dermatology, University Hospital Kiel, Kiel, Germany.
  • Axel Hauschild
    Department of Dermatology, University Hospital Kiel, Kiel, Germany.
  • Michael Weichenthal
    Department of Dermatology, University Hospital Kiel, Kiel, Germany.
  • Jochen S Utikal
    Department of Dermatology, Heidelberg University, Mannheim, Germany; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Keywords

External Resources

Popular Topics
Recent Journals